Efficacy of tocilizumab monotherapy after ultrashort glucocorticoid administration to treat giant cell arteritis: three-year follow-up
Drug-free remission was maintained in all but two patients entering long-term extension. This relapse rate is substantially lower than reported in the randomized controlled trials. Patient characteristics (exclusively new diagnoses), and the intensive initial treatment may explain the lasting remission.
Authors
- Luca Seitz (ORCID: https://orcid.org/0000-0002-5051-1445)
- Godehard Scholz
- Stephan Reichenbach (ORCID: https://orcid.org/0000-0001-8098-6567)
- Lisa Christ (ORCID: https://orcid.org/0000-0002-7358-2051)
- Lukas Bütikofer (ORCID: https://orcid.org/0000-0002-0801-746X)
- Peter M. Villiger (ORCID: https://orcid.org/0000-0002-8859-9964)
- Florian Kollert (ORCID: https://orcid.org/0009-0008-5252-3918)
Institutions
- University of Bern (CH)
- Bern University of Applied Sciences (CH)
- University Hospital of Bern (CH)
- University Hospital of Basel (CH)
- Institute of Social and Preventive Medicine (CH)
- Center for Rheumatology (US)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2025-06-06
- DOI
- https://doi.org/10.1093/rheumatology/keaf317
- Citations
- 1
- Primary Topic
- Vasculitis and related conditions
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- University of Bern